KNSA vs. BMRN
Compare and contrast key facts about Kiniksa Pharmaceuticals, Ltd. (KNSA) and BioMarin Pharmaceutical Inc. (BMRN).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: KNSA or BMRN.
Correlation
The correlation between KNSA and BMRN is 0.45, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
KNSA vs. BMRN - Performance Comparison
Loading data...
Key characteristics
KNSA:
0.58
BMRN:
-0.81
KNSA:
1.22
BMRN:
-0.97
KNSA:
1.15
BMRN:
0.85
KNSA:
0.67
BMRN:
-0.46
KNSA:
1.56
BMRN:
-1.20
KNSA:
17.93%
BMRN:
23.97%
KNSA:
50.57%
BMRN:
34.71%
KNSA:
-83.06%
BMRN:
-90.58%
KNSA:
-15.84%
BMRN:
-60.53%
Fundamentals
KNSA:
$1.90B
BMRN:
$11.47B
KNSA:
-$0.24
BMRN:
$2.70
KNSA:
4.05
BMRN:
3.89
KNSA:
4.26
BMRN:
1.98
KNSA:
$481.17M
BMRN:
$2.94B
KNSA:
$389.86M
BMRN:
$2.32B
KNSA:
-$14.97M
BMRN:
$738.30M
Returns By Period
In the year-to-date period, KNSA achieves a 31.60% return, which is significantly higher than BMRN's -10.45% return.
KNSA
31.60%
39.57%
13.87%
33.28%
3.12%
N/A
BMRN
-10.45%
4.51%
-12.24%
-27.36%
-9.44%
-7.01%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
KNSA vs. BMRN — Risk-Adjusted Performance Rank
KNSA
BMRN
KNSA vs. BMRN - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Kiniksa Pharmaceuticals, Ltd. (KNSA) and BioMarin Pharmaceutical Inc. (BMRN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
KNSA vs. BMRN - Dividend Comparison
Neither KNSA nor BMRN has paid dividends to shareholders.
Drawdowns
KNSA vs. BMRN - Drawdown Comparison
The maximum KNSA drawdown since its inception was -83.06%, smaller than the maximum BMRN drawdown of -90.58%. Use the drawdown chart below to compare losses from any high point for KNSA and BMRN. For additional features, visit the drawdowns tool.
Loading data...
Volatility
KNSA vs. BMRN - Volatility Comparison
Kiniksa Pharmaceuticals, Ltd. (KNSA) has a higher volatility of 23.23% compared to BioMarin Pharmaceutical Inc. (BMRN) at 10.67%. This indicates that KNSA's price experiences larger fluctuations and is considered to be riskier than BMRN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
KNSA vs. BMRN - Financials Comparison
This section allows you to compare key financial metrics between Kiniksa Pharmaceuticals, Ltd. and BioMarin Pharmaceutical Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
KNSA vs. BMRN - Profitability Comparison
KNSA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 76.13M and revenue of 137.79M. Therefore, the gross margin over that period was 55.3%.
BMRN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, BioMarin Pharmaceutical Inc. reported a gross profit of 593.59M and revenue of 745.15M. Therefore, the gross margin over that period was 79.7%.
KNSA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 13.27M and revenue of 137.79M, resulting in an operating margin of 9.6%.
BMRN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, BioMarin Pharmaceutical Inc. reported an operating income of 223.89M and revenue of 745.15M, resulting in an operating margin of 30.1%.
KNSA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Kiniksa Pharmaceuticals, Ltd. reported a net income of 8.54M and revenue of 137.79M, resulting in a net margin of 6.2%.
BMRN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, BioMarin Pharmaceutical Inc. reported a net income of 185.69M and revenue of 745.15M, resulting in a net margin of 24.9%.